Conflict Should DQ Katten In IP Row, Valeant Tells Fed. Circ.
Katten Muchin Rosenman LLP should be disqualified from three ongoing drug patent appeals, Valeant Pharmaceuticals International Inc. told a Federal Circuit panel Wednesday, arguing that when the firm hired two Alston...To view the full article, register now.
Already a subscriber? Click here to view full article